Table 2.
Demographic data, postoperative infectious complications, and clinical outcomes endpoints of Group 2 patients divided into nonfungal and invasive fungal subgroups (n, %, mean ± SD).
| Nonfungal (n = 39) |
Invasive fungala (n = 10) |
p value∗ | |
|---|---|---|---|
| Age, years (mean ± SD) | 72.25 ± 14.29 | 72.9 ± 14.9 | 0.15 |
| Weight, Kg (mean ± SD) | 72.9 ± 12.9 | 72.6 ± 13.57 | 0.9 |
| Gender (male) | 21/39 (53.8%) | 3/10 (30%) | 0.4 |
| Type of upper GITb surgery | |||
| Total gastrectomy | 22/39 (56.4) | 4/10 (40%) | 0.61 |
| Partial gastrectomy | 17/39 (43.6%) | 6/10 (60%) | 0.5 |
| Underlying condition (%) | |||
| Without chronic disease | 10/39 (25.6%) | 5/10 (50%) | 0.08 |
| Diabetes mellitus | 16/39 (41%) | 3/10 (30%) | 0.08 |
| CIHDc | 12/39 (30.7%) | 2/10 (20%) | 0.16 |
| Hypertension | 1/39 (2.5%) | 0 | NA |
| Chronic therapy (%) | |||
| Without chronic therapy | 10/39 (25.6%) | 5/10 (50%) | 0.04 |
| Statins | 13/39 (33.3%) | 3/10 (30%) | 0.48 |
| ACEd | 16/39 (41%) | 2/10 (20%) | 0.03 |
| Postoperative complications | |||
| Intraperitoneal leak (n, %) (documented) | 27/39 (69.2%) | 9/10 (90%) | 0.01 |
| Leak location (n, %) | |||
| Gastroesophageal junction | 8/39 (34.8%) | 8/10 (80%) | 0.02 |
| Gastrointestinal anastomosis | 7/39 (30.4%) | 1/10 (10%) | 0.01 |
| Duodenum/small bowel | 8/39 (34.8%) | 1/10 (10%) | 0.02 |
| Intra-abdominal abscesses (n, %) | 16/39 (41%) | 9/10 (90%) | 0.006 |
| Presence of pleural effusion (n, %) | 4/39 (10.3%) | 4/10 (40%) | 0.04 |
| Clinical outcome endpoints | |||
| APACHE 24e (units, mean ± SD) | 24.51 ± 6.06 | 24.2 ± 5.37 | 0.67 |
| TISS score 24e (units, mean ± SD) | 22.48 ± 6.03 | 22.2 ± 5.37 | 0.72 |
| ICU length of stay (day, mean ± SD) | 11.6 ± 1.5 | 13.9 ± 1.4 | 0.65 |
| Hospital length of stay (day, mean ± SD) | 34.84 ± 2.6 | 25.2 ± 1.5 | 0.11 |
| ICU mortality (%) | 6/39 (15.4%) | 5/10 (50%) | 0.03 |
∗ p < 0.05 was found to be statistically significant. aInvasive fungal (Candida) complications: Candida peritonitis, candidemia, and Candida empyema. bGastrointestinal tract; cCIHD: chronic ischemic heart disease; dACE: angiotensin-converting enzyme. eWithin 24 hours of ICU admission.